Cited by 386Osteoarthritis Treatment and MechanismsTelomeres, Telomerase, and SenescenceHip disorders and treatments

The role of chondrocyte senescence in osteoarthritis

Open access
Price, Jo S., Waters, Jasmine G., Darrah, Clare, Pennington, Caroline, Edwards, Dylan R., Donell, Simon T., Clark, Ian M.·2002·Aging Cell

Abstract

Summary: Replicative senescence occurs when normal somatic cells stop dividing. Senescent cells remain viable, but show alterations in phenotype, e.g. altered expression of matrix metalloproteinases ( MMPs ); these enzymes are known to be involved in cartilage destruction. It is assumed that cells deplete their replicative potential during aging, and age is a major risk factor for osteoarthritis (OA). Therefore, we hypothesized that chondrocytes in aging or diseased cartilage become senescent with associated phenotypic changes contributing to development or progression of OA. Articular cartilage was obtained from OA patients undergoing arthroplasty, with ‘normal’ cartilage from trauma surgery for hip fracture. Senescent cells were identified using the senescence‐associated β‐galactosidase (SA‐β‐gal) marker. Telomere length was assessed using Southern blot. MMP expression was measured at the mRNA level using Taqman® RT‐PCR. No SA‐β‐gal staining was observed in control cartilage regardless of patient age. In contrast, SA‐β‐gal staining was observed in damaged OA cartilage adjacent to the lesion. Cultured chondrocytes isolated from sites near a lesion contained a greater percentage of SA‐β‐gal positive cells than cultures isolated from distal sites or normal cartilage. Mean telomere length was shorter in cells near the lesion compared to distal sites in the same joint; thus the former population has undergone cell division. The expression of collagenases MMP‐1 , ‐8 and ‐13 and tissue inhibitor of metalloproteinases (TIMP)‐1 was altered in OA cartilage, but no difference was detected between lesion and distal sites in the same joint (i.e. no correlation was found between senescent cells and proteinase/inhibitor expression).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1474-9728.2002.00008.x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Price, J. S., Waters, J. G., Darrah, C., Pennington, C., Edwards, D. R., Donell, S. T., & Clark, I. M.
Affiliations
  • University of East Anglia (GB)
  • Norfolk and Norwich University Hospital (GB)
Corresponding author
Clark, Ian M.
Venue
Aging Cell
Publisher
Wiley
Published
2002-09-15
Volume
1
Issue
1
Pages
57-65
ISSN
  • 1474-9718 (ISSN-L)
  • 1474-9726
OpenAlex
W2032691826
Cited by
386
References
31
Citations by year
2026: 14 · 2025: 22 · 2024: 32 · 2023: 23 · 2022: 25 · 2021: 16 · 2020: 31 · 2019: 30 · 2018: 16 · 2017: 24 · 2016: 12 · 2015: 18 · 2014: 12 · 2013: 14 · 2012: 15
FWCI
2.60
Type
journal article
Language
en
Open access
Locations
  • Aging Cell (publishedVersion)
  • PubMed (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders
Lawrence Berkeley National Laboratory
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Surgery › Hip disorders and treatments
Keywords
chondrocyte senescence, osteoarthritis, replicative senescence, senescence-associated β-galactosidase, telomere length, matrix metalloproteinases, collagenase, MMP-1, MMP-8, MMP-13, TIMP-1, articular cartilage, cartilage destruction, aging
MeSH terms
Aged, Aged, 80 and over, beta-Galactosidase, Cartilage, Articular, Cells, Cultured, Humans, Middle Aged, Osteoarthritis, RNA, Messenger, Biomarkers, Telomere, Cellular Senescence, Tissue Inhibitor of Metalloproteinase-1, Chondrocytes, Matrix Metalloproteinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review